GlassScriptPhysician profile
Yan Zhao
NPI 1124462379
$1,072.46
in general payments reported to CMS, 2019-2025
27 companies · $68.49 in 2025
The $68.49 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $381 · 2020: $309 · 2021: $314 · 2025: $68.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $68.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $68.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $121.62 | 2019-2021 | |
| Amgen INC. | $99.99 | 2019 | |
| Janssen Biotech, INC. | $88.08 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $87.61 | 2019-2021 | |
| Incyte Corporation | $84.34 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $68.49 | 2025 | Imfinzi |
| Novartis Pharmaceuticals Corporation | $64.50 | 2020-2021 | |
| Genzyme Corporation | $42.56 | 2019-2020 | |
| Celgene Corporation | $39.83 | 2021 | |
| Exelixis INC. | $36.34 | 2019-2021 | |
| Seagen INC. | $35.58 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $34.98 | 2021 | |
| Pharmacyclics LLC, An Abbvie Company | $30.31 | 2019-2021 | |
| Abbvie INC. | $24.62 | 2020-2021 | |
| Secura Bio, INC. | $23.62 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $23.61 | 2021 | |
| Tesaro, INC. | $22.47 | 2019 | |
| Daiichi Sankyo INC. | $21.64 | 2019 | |
| Stemline Therapeutics INC. | $17.88 | 2019 | |
| Kyowa Kirin, INC. | $15.82 | 2020 | |
| Lilly USA, LLC | $15.51 | 2019 | |
| Emd Serono, INC. | $14.43 | 2020 | |
| Eisai INC. | $12.52 | 2020 | |
| Advanced Accelerator Applications | $11.83 | 2019 | |
| Genentech USA, INC. | $11.65 | 2019 | |
| Global Blood Therapeutics, INC. | $11.39 | 2020 | |
| Dova Pharmaceuticals | $11.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yan Zhao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.